BioSig Technologies Inc Stock Price, News & Analysis

BioSig Technologies, Inc. (Nasdaq: BSGM) will present at the Benzinga Biotech Small Cap Conference on March 24-25, 2021. Kenneth L. Londoner, Chairman and CEO, is scheduled to speak on March 25th at 12:20 PM ET. He will discuss recent milestones related to the PURE EP™ System, an advanced platform aimed at improving cardiac ablations. Over 40 physicians have utilized the system in more than 600 patient cases across eight clinical sites. One-on-one meetings with management can be scheduled through links provided in the release.

BioSig Technologies (Nasdaq: BSGM) has been invited to the Oppenheimer 31st Annual Healthcare Conference on March 18, 2021. Kenneth L. Londoner, Chairman and CEO, will participate in a virtual fireside chat at 8:00 AM ET and is available for investor meetings. BioSig's PURE EP™ System enhances signal fidelity for cardiac ablation procedures, with over 38 physicians completing more than 580 cases across 7 clinical sites. A replay of the chat will be accessible for 90 days post-event.

BioSig Technologies, a medical technology firm, will present at the 33rd Annual Virtual ROTH Conference from March 15-17, 2021. CEO Kenneth L. Londoner will discuss the company's progress and provide an overview of BioSig's innovative PURE EP™ System, which improves ECG signal fidelity and has been used in over 580 patient cases by more than 38 physicians. The presentation will be accessible online starting March 10, 2021, and available for 90 days. The conference, featuring numerous companies, attracts institutional investors and analysts.

BioSig Technologies, Inc. (NASDAQ: BSGM) announced the allowance of a utility patent for its subsidiary NeuroClear Technologies, licensed from the Mayo Foundation. This patent focuses on methods to enhance hypertension treatment through electroporation. It complements BioSig's expanding portfolio of nine allowed patents and 16 pending patent applications related to their PURE EP™ System. The company aims to develop its N-SENSE™ platform to address neurological conditions, utilizing innovative sensing designs and algorithms.

BioSig Technologies has appointed Brenda Castrodad as the new head of its Human Resources department to support the demand for its PURE EP System. With experience in life sciences at both start-ups and Fortune 500 companies, she previously transformed HR at TissueTech and expanded HeartWare's workforce significantly. Castrodad's expertise is expected to enhance talent acquisition and employee engagement amidst BioSig's growth trajectory. CEO Kenneth L. Londoner expressed confidence in her ability to drive innovation and success within the company.

BioSig Technologies, a medical technology firm, has entered into three new evaluation agreements for its PURE EP™ System, reducing assessment cycles to 90 days. This shift follows successful evaluations in 2020 and aims to facilitate rapid commercialization. The new clinical sites, including prestigious hospitals like New York-Presbyterian and Michigan Medicine, will enhance the system's deployment. Over 500 patient cases have already been recorded using the PURE EP™ System. The company anticipates increased activity in 2021, driven by declining COVID-19 cases.

BioSig Technologies, Inc. (Nasdaq: BSGM) has announced its participation in the Virtual Investor Conference Small and Microcap Showcase on February 4, 2021. During the event, Kenneth L. Londoner, Chairman and CEO, will present a corporate overview, including updates on the rollout of their innovative PURE EP™ System. Over 470 patient procedures have been successfully conducted using this system across seven clinical sites in the U.S. The presentation is scheduled for 11:30 AM Eastern time.

BioSig Technologies (NASDAQ: BSGM) will showcase its PURE EP System at the 26th Annual International Atrial Fibrillation Symposium on January 29, 2021. G. Joseph Gallinghouse, M.D., from the Texas Cardiac Arrhythmia Institute, will present clinical observations from over 470 patient cases. The event is accessible virtually, offering free registration, and aims to highlight advancements in atrial fibrillation technology. Kenneth L. Londoner, CEO of BioSig, expresses gratitude for the opportunity to engage with a broader audience this year.

BioSig Technologies, a medical technology firm, has been featured in EP Lab Digest for its PURE EP™ System, addressing challenges in electrophysiology (EP). The article emphasizes issues like signal loss and inadequate signal-to-noise ratios in EP labs. The PURE EP™ System's advanced technology helps improve signal fidelity, as demonstrated by recent research where 85% of signals were rated as equivalent or superior. CEO Kenneth Londoner noted the importance of this recognition and plans for increased physician collaborations in 2021.